EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 2c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.54), $0.02 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.5 million versus the consensus estimate of $10.06 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
• JPMorgan Starts Bytes Technology Group PLC (BYIT:LN) at Underweight
• UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy